
1. j antimicrob chemother. 2019 nov 1;74(11):3240-3244. doi: 10.1093/jac/dkz340.

in vitro activity ferroquine artemisinin-based combination therapy
(act)-resistant plasmodium falciparum isolates cambodia.

mairet-khedim m(1)(2), nardella f(3), khim n(1), kim s(1), kloeung n(1), ke s(1),
kauy c(1), eam r(1), khean c(1), pellet a(4), leboulleux d(4), leang r(5),
ringwald p(6), barale jc(2)(7), leroy d(8), menard d(3), witkowski b(1)(2).

author information: 
(1)malaria molecular epidemiology unit, pasteur institute cambodia, phnom
penh, cambodia.
(2)malaria translational research unit, institut pasteur, paris, france.
(3)biology host-parasite interactions unit, institut pasteur, paris, france.
(4)evotec id, marcy-l'étoile, france.
(5)national center malariology, entomology malaria control, phnom penh,
cambodia.
(6)world health organization, geneva, switzerland.
(7)unité de microbiologie structurale, institut pasteur, cnrs, université de
paris, paris, france.
(8)medicines malaria venture, geneva, switzerland.

background: cambodia epicentre resistance emergence virtually all
antimalarial drugs. selection spread parasites resistant to
artemisinin-based combination therapy (act) major threat malaria
elimination, hence need renew pool effective treatments.
objectives: determine whether act resistance haplotypes could effect
on ferroquine vitro antimalarial activity.
methods: vitro susceptibility ferroquine measured 80 isolates 
cambodia characterized molecular resistance profile artemisinin,
piperaquine mefloquine.
results: among 80 isolates tested, overall median (iqr) ic50 of
ferroquine 10.9 nm (8.7-18.3). ferroquine median (iqr) ic50 8.9 nm
(8.1-11.8) pfk13 wt parasites 12.9 nm (9.5-20.0) pfk13 c580y
parasites amplification pfpm2 pfmdr1 genes. median (iqr) ic50 
of ferroquine pfk13 c580y parasites amplification pfpm2 gene 
17.2 nm (14.5-20.5) versus 9.1 nm (7.9-10.7) pfk13 c580y parasites with
amplification pfmdr1 gene.
conclusions: ferroquine exerts promising efficacy act-resistant isolates.
whereas pfpm2 amplification associated highest parasite tolerance to
ferroquine, susceptibility range observed accordance those
measured act resistance-free areas. enables consideration ferroquine
as relevant therapeutic option act-resistant malaria.

© author(s) 2019. published oxford university press behalf the
british society antimicrobial chemotherapy. rights reserved. for
permissions, please email: journals.permissions@oup.com.

doi: 10.1093/jac/dkz340 
pmid: 31518407  [indexed medline]

